Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C20H25NO3.ClH |
| Molecular Weight | 363.878 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.CCN(CC)CCOC(=O)C(O)(C1=CC=CC=C1)C2=CC=CC=C2
InChI
InChIKey=ZCEHOOLYWQBGQO-UHFFFAOYSA-N
InChI=1S/C20H25NO3.ClH/c1-3-21(4-2)15-16-24-19(22)20(23,17-11-7-5-8-12-17)18-13-9-6-10-14-18;/h5-14,23H,3-4,15-16H2,1-2H3;1H
Benactyzine, an anticholinergic drug, had been used as an antidepressant in the treatment of depression and associated anxiety. It is no longer used in medicine due to its ineffectiveness but is widely used in scientific research. Benactyzine is a muscarinic antagonist which also inhibits the nicotinic acetylcholine receptor.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL2094109 |
|||
Target ID: Nicotinic acetylcholine receptor |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | Deprol Approved Usetreatment of depression |
|||
| Primary | Anxiolit plus Approved UseAnxiety states of tension and excitement change of symptoms discomfort of the gastrointestinal tract, the cardiovascular system and the urinary tract due to psychological causes (psychovegetative complaints) |
Doses
| Dose | Population | Adverse events |
|---|---|---|
1300 mg single, oral Overdose Dose: 1300 mg Route: oral Route: single Dose: 1300 mg Sources: Page: p.86 |
unknown n = 1 |
Disc. AE: Psychosis... AEs leading to discontinuation/dose reduction: Psychosis Sources: Page: p.86 |
200 mg single, oral Overdose Dose: 200 mg Route: oral Route: single Dose: 200 mg Sources: Page: p.86 |
healthy n = 1 |
Disc. AE: Delirium... AEs leading to discontinuation/dose reduction: Delirium (severe) Sources: Page: p.86 |
AEs
| AE | Significance | Dose | Population |
|---|---|---|---|
| Psychosis | Disc. AE | 1300 mg single, oral Overdose Dose: 1300 mg Route: oral Route: single Dose: 1300 mg Sources: Page: p.86 |
unknown n = 1 |
| Delirium | severe Disc. AE |
200 mg single, oral Overdose Dose: 200 mg Route: oral Route: single Dose: 200 mg Sources: Page: p.86 |
healthy n = 1 |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Meprobamate-benactyzine (Deprol) and placebo in two depressed outpatient populations. | 1969 Mar-Apr |
|
| The influence of anticholinergic drug selection on the effectiveness of oximes against soman-induced supralethal poisoning in mice. | 2001 |
|
| Inhibition effects of benactyzine and drofenine on human serum butyrylcholinesterase. | 2001 Feb 1 |
|
| A comparison of the neuroprotective efficacy of pharmacological pretreatment and antidotal treatment in soman-poisoned rats. | 2003 |
|
| Neuroprotective efficacy of pharmacological pretreatment and antidotal treatment in tabun-poisoned rats. | 2003 Mar 14 |
|
| Therapeutic efficacy of different antidotal mixtures against poisoning with GF-agent in mice. | 2004 |
|
| Acute experimental tabun-induced intoxication and its therapy in rats. | 2004 Mar |
|
| Protection and inflammatory markers following exposure of guinea pigs to sarin vapour: comparative efficacy of three oximes. | 2004 Nov-Dec |
|
| The influence of oxime and anticholinergic drug selection on the potency of antidotal treatment to counteract acute toxic effects of tabun in mice. | 2006 Jan |
|
| [The sexual function of mature rat males after prenatal modulation of cholinergic system]. | 2008 May |
|
| Paraoxon attenuates vascular smooth muscle contraction through inhibiting Ca2+ influx in the rabbit thoracic aorta. | 2010 |
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C29704
Created by
admin on Fri Dec 15 14:59:54 GMT 2023 , Edited by admin on Fri Dec 15 14:59:54 GMT 2023
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
SUB00693MIG
Created by
admin on Fri Dec 15 14:59:54 GMT 2023 , Edited by admin on Fri Dec 15 14:59:54 GMT 2023
|
PRIMARY | |||
|
26R628272Q
Created by
admin on Fri Dec 15 14:59:54 GMT 2023 , Edited by admin on Fri Dec 15 14:59:54 GMT 2023
|
PRIMARY | |||
|
m2301
Created by
admin on Fri Dec 15 14:59:54 GMT 2023 , Edited by admin on Fri Dec 15 14:59:54 GMT 2023
|
PRIMARY | Merck Index | ||
|
66448
Created by
admin on Fri Dec 15 14:59:54 GMT 2023 , Edited by admin on Fri Dec 15 14:59:54 GMT 2023
|
PRIMARY | |||
|
C78059
Created by
admin on Fri Dec 15 14:59:54 GMT 2023 , Edited by admin on Fri Dec 15 14:59:54 GMT 2023
|
PRIMARY | |||
|
16339
Created by
admin on Fri Dec 15 14:59:54 GMT 2023 , Edited by admin on Fri Dec 15 14:59:54 GMT 2023
|
PRIMARY | |||
|
100000084992
Created by
admin on Fri Dec 15 14:59:54 GMT 2023 , Edited by admin on Fri Dec 15 14:59:54 GMT 2023
|
PRIMARY | |||
|
314518
Created by
admin on Fri Dec 15 14:59:54 GMT 2023 , Edited by admin on Fri Dec 15 14:59:54 GMT 2023
|
PRIMARY | RxNorm | ||
|
DTXSID8052774
Created by
admin on Fri Dec 15 14:59:54 GMT 2023 , Edited by admin on Fri Dec 15 14:59:54 GMT 2023
|
PRIMARY | |||
|
200-324-4
Created by
admin on Fri Dec 15 14:59:54 GMT 2023 , Edited by admin on Fri Dec 15 14:59:54 GMT 2023
|
PRIMARY | |||
|
57-37-4
Created by
admin on Fri Dec 15 14:59:54 GMT 2023 , Edited by admin on Fri Dec 15 14:59:54 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD
